The data are available suggesting that functional impairments in neuronal cells due to weakening of the GLP-1 system are likely to alter the activity of other neurotransmitter systems, primarily dopaminergic, which causes disintegration of the brain signaling network and enhances insulin resistance, dyslipidemia and oxidative stress, and exacerbates the metabolic disorders. This evidence concerns the gene GCG and Other metabolic disease.